Pieris Pharmaceuticals Gmbh

Xl-protein Gmbh

Pieris Ag

Michaela Gebauer

Arne Skerra

Gabriele Matschiner

Martin Huelsmeyer

Dominik Hinz

Sabine Rauth

Qing Dong

The present invention relates to a novel library for the generation of muteins and to novel muteins derived from human lipocalin 2 (Lcn2, hNGAL) and related proteins that bind a given target with detectable affinity. The invention also relates to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. For example, such muteins may serve to bind and deplete pathological forms of natural biomolecules such as the amyloid beta peptide in Alzheimer's disease or may target the fibronectin extra-domain B, which is associated with tumor neovasculature.

Muteins of human lipocalin 2 (Lcn2, hNGAL) with affinity for a given target

A protein comprising (i) a domain of the Platelet-Derived Growth Factor receptor (PDGFR) and (ii) a domain of the Vascular Endothelial Growth Factor receptor (VEGFR) is provided. In a preferred embodiment, said domain of PDGFR and said domain of VEGFR are attached by a linker consisting of proline, alanine and serine. The domain of PDGFR and said domain of VEGFR can also be attached by a linker consisting of proline and alanine. Compositions comprising the proteins, as well as therapeutic uses thereof are also provided.

PASylated VEGFR/PDGFR fusion proteins and their use in therapy

Muteins of human lipocalin 2 (Lcn2,hNGAL) with affinity for a given target

Muteins of human lipocalin 2 (LcnC,hNGAL) with affinity for a given target

Growing community of inventors

Leipzig, Germany

Michaela Gebauer